This segment focuses on the research, development, manufacturing, and commercialization of human pharmaceuticals. Orion's R&D activities in this area include drug discovery, clinical trials, and regulatory submissions. The company utilizes various technologies, including advanced formulation techniques for inhalation products (Easyhaler®) and innovative approaches to treat diseases like prostate cancer (Nubeqa®) and Parkinson's disease (Stalevo®). The segment addresses significant patient needs in oncology, neurology, and respiratory diseases, aiming to improve patient outcomes and quality of life. Orion's market positioning is strong in Finland and internationally, with a focus on prescription drugs and self-care products. Future opportunities include expanding the product portfolio, entering new markets, and developing innovative therapies through partnerships and collaborations, such as the one with Propeller Health for the Easyhaler® product portfolio. Regulatory aspects include obtaining approvals from various health authorities, and clinical trials are essential for demonstrating the safety and efficacy of new drugs.

This segment is dedicated to the development, manufacturing, and marketing of veterinary drugs. Orion's R&D efforts focus on creating innovative solutions for animal health, including drugs for various species. The company utilizes its expertise in formulation and drug delivery to develop effective and safe veterinary products. The therapeutic areas covered include pain management, sedation, and other conditions affecting companion animals and livestock. The segment aims to improve animal health and well-being, contributing to better outcomes for pets and livestock. Orion's market position in the veterinary pharmaceutical sector is strengthened by its diverse product portfolio and partnerships with other international companies. Future growth opportunities include expanding the product range, entering new geographic markets, and developing novel veterinary therapies. Regulatory aspects involve obtaining approvals from veterinary health authorities, and clinical trials are conducted to ensure the safety and efficacy of the products.

This segment focuses on the production and sale of Active Pharmaceutical Ingredients (APIs) for both generic and proprietary drugs, as well as providing contract manufacturing services. Orion's R&D activities in this area involve process development, optimization, and quality control of API manufacturing. The company utilizes advanced chemical synthesis and manufacturing technologies to produce high-quality APIs. This segment supports the pharmaceutical industry by providing essential ingredients and manufacturing capabilities. The patient impact is indirect, as the APIs and manufacturing services contribute to the availability of essential medicines. Orion's market positioning is based on its expertise in API production and contract manufacturing services. Future opportunities include expanding the API portfolio, increasing manufacturing capacity, and securing new contract manufacturing agreements. Regulatory aspects include compliance with Good Manufacturing Practices (GMP) and other relevant regulations. The segment also involves collaborations with other pharmaceutical companies.